Serial Monitoring with a Tissue-Free, Epigenetic ctDNA Assay Identifies Early Molecular Progression & Improves Prediction of Immune Checkpoint Inhibitor Response
1:30 pm - Thursday 5th February 2026
- Early identification of non-responders to immune checkpoint inhibitors is critical, yet radiographic assessments can lag and miss true biological progression
- This study shows that serial monitoring with a tumor-naive, methylation-based ctDNA assay more sensitively detects molecular progression, outperforming RECIST and identifying treatment failure nearly two months earlier
- Longitudinal ctDNA dynamics provide independent prognostic value and enable more timely, informed clinical decisions
